| Ytd | 9.79% | |
| 1y | 119.71% |
| Open | 17.15 | Prev Close | 17.14 | Low | 16.80 | High | 17.34 | Mkt Cap | 1.08B |
| Vol | 2.94M | Avg Vol | 944.41K | EPS | -1.07 | P/E | N/A | Forward P/E | -6.36 |
| Beta | 1.45 | Short Ratio | 12.92 | Inst. Own | 116.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 20.74 | 200-d Avg | 18.24 | 1yr Est | 50.13 |
JBIO News
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcrip
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences,
Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significan
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.76) per share which missed the analy
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week sub
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
UBS analyst Michael Yee initiates coverage on Jade Biosciences (NASDAQ:JBIO) with a Buy rating an
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the st
Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage bio
Stocks to watch: CIEN, DOCU, LULU, report earnings today. MRAAF introduces world's first 100Vdc
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage bio
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises
Jade Biosciences NASDAQ: JBIO said interim results from a Phase 1 healthy volunteer study of JADE101
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunt
Jade Biosciences, Inc. (NASDAQ:JBIO) reported interim Phase 1 results for JADE101 in immunoglobulin
Jade Biosciences reports Phase 1 JADE101 data showing sustained IgA reductions in IgAN, while analys
BTIG analyst Julian Harrison maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and raises the p
HC Wainwright & Co. analyst Arthur He maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and
U.S. stock futures up, Nasdaq surges 0.35%, with Taylor Morrison's buyout announcement. Other pr
JADE101 is designed with ultra-high binding affinity to selectively block APRIL, a key driver of pat
SAN FRANCISCO and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage bio
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, In
BTIG analyst Julian Harrison reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage bi
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication p
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, In
SAN FRANCISCO and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, In
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences,
SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences,
Top analysts updated ratings for MU, EPAM, WLTH, OKUR, BLDR, DMRC, JBIO, CRCL. See changes and ratin
